Anna Jakubowska

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5100552/publications.pdf

Version: 2024-02-01

365 papers	24,412 citations	11651 70 h-index	11052 137 g-index
389 all docs	389 docs citations	389 times ranked	24311 citing authors

#	Article	IF	Citations
1	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6
2	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
3	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
4	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncology, 2022, 8, e216744.	7.1	51
5	Risk of Second Primary Thyroid Cancer in Women with Breast Cancer. Cancers, 2022, 14, 957.	3.7	5
6	Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor. Hereditary Cancer in Clinical Practice, 2022, 20, 11.	1.5	4
7	The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations. British Journal of Cancer, 2022, 127, 84-91.	6.4	4
8	Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland. Hereditary Cancer in Clinical Practice, 2022, 20, 12.	1.5	0
9	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	8.2	19
10	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
11	Population-based targeted sequencing of 54 candidate genes identifiesPALB2as a susceptibility gene for high-grade serous ovarian cancer. Journal of Medical Genetics, 2021, 58, 305-313.	3.2	26
12	Lung Cancer Occurrenceâ€"Correlation with Serum Chromium Levels and Genotypes. Biological Trace Element Research, 2021, 199, 1228-1236.	3.5	13
13	Blood cadmium levels as a marker for early lung cancer detection. Journal of Trace Elements in Medicine and Biology, 2021, 64, 126682.	3.0	28
14	Mild X-linked Alport syndrome due to the COL4A5 G624D variant originating in the Middle Ages is predominant in Central/East Europe and causes kidney failure in midlife. Kidney International, 2021, 99, 1451-1458.	5.2	21
15	Prevalence of germline TP53 variants among early-onset breast cancer patients from Polish population. Breast Cancer, 2021, 28, 226-235.	2.9	10
16	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	6.4	5
17	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
18	Breast Cancer Risk Genes â€" Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	27.0	532

#	Article	IF	Citations
19	Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer. Cancers, 2021, 13, 849.	3.7	13
20	Serum Selenium Level Predicts 10-Year Survival after Breast Cancer. Nutrients, 2021, 13, 953.	4.1	14
21	PALB2 mutations and prostate cancer risk and survival. British Journal of Cancer, 2021, 125, 569-575.	6.4	18
22	COL12A1 Single Nucleotide Polymorphisms rs240736 and rs970547 Are Not Associated with Temporomandibular Joint Disc Displacement without Reduction. Genes, 2021, 12, 690.	2.4	7
23	A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report. European Journal of Human Genetics, 2021, 29, 1354-1358.	2.8	9
24	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	2.4	16
25	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6
26	Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers. Cancers, 2021, 13, 3345.	3.7	6
27	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 51.e1-51.e17.	1.3	34
28	Serum Selenium Level and 10-Year Survival after Melanoma. Biomedicines, 2021, 9, 991.	3.2	8
29	Low Blood-As Levels and Selected Genotypes Appears to Be Promising Biomarkers for Occurrence of Colorectal Cancer in Women. Biomedicines, 2021, 9, 1105.	3.2	0
30	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7
31	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	6.4	9
32	Influence of the Levels of Arsenic, Cadmium, Mercury and Lead on Overall Survival in Lung Cancer. Biomolecules, 2021, 11, 1160.	4.0	23
33	COL5A1 RS12722 Is Associated with Temporomandibular Joint Anterior Disc Displacement without Reduction in Polish Caucasians. Cells, 2021, 10, 2423.	4.1	8
34	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	2.5	19
35	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	3.3	2
36	Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?. Cancers, 2021, 13, 5464.	3.7	1

#	Article	IF	Citations
37	Association of ABCA4 Gene Polymorphisms with Cleft Lip with or without Cleft Palate in the Polish Population. International Journal of Environmental Research and Public Health, 2021, 18, 11483.	2.6	4
38	Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland. Biomedicines, 2021, 9, 1628.	3.2	19
39	Blood arsenic levels and the risk of familial breast cancer in Poland. International Journal of Cancer, 2020, 146, 2721-2727.	5.1	18
40	BRCA1 promoter methylation in peripheral blood is associated with the risk of tripleâ€negative breast cancer. International Journal of Cancer, 2020, 146, 1293-1298.	5.1	33
41	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
42	Biosynthesis pathway of indole-3-acetyl-myo-inositol during development of maize (Zea mays L.) seeds. Journal of Plant Physiology, 2020, 245, 153082.	3.5	9
43	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
44	Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast, lung and colon cancer risk in polish population. Hereditary Cancer in Clinical Practice, 2020, 18, 16.	1.5	14
45	Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials. Cardiovascular Therapeutics, 2020, 2020, 1-11.	2.5	9
46	Association of Estrogen Receptor 1 and Tumor Necrosis Factor Î± Polymorphisms with Temporomandibular Joint Anterior Disc Displacement without Reduction. Disease Markers, 2020, 2020, 1-9.	1.3	14
47	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	6.2	39
48	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. Npj Breast Cancer, 2020, 6, 44.	5.2	5
49	Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland. Cancers, 2020, 12, 2321.	3.7	11
50	Mutations in ATM , NBN and BRCA2 predispose to aggressive prostate cancer in Poland. International Journal of Cancer, 2020, 147, 2793-2800.	5.1	27
51	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
52	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
53	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
54	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	2.5	24

#	Article	IF	Citations
55	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
56	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8.	5.0	41
57	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. Breast Cancer Research and Treatment, 2020, 181, 423-434.	2.5	14
58	Annexin V in children with idiopathic nephrotic syndrome treated with cyclosporine A. Advances in Clinical and Experimental Medicine, 2020, 29, 603-609.	1.4	2
59	Influence of the selenium level on overall survival in lung cancer. Journal of Trace Elements in Medicine and Biology, 2019, 56, 46-51.	3.0	25
60	Allelic modification of breast cancer risk in women with an NBN mutation. Breast Cancer Research and Treatment, 2019, 178, 427-431.	2.5	6
61	Assessment of the Concentration of Bone Metabolism Markers: Sclerostin and FGF-23 in Children with Idiopathic Nephrotic Syndrome Treated with Glucocorticosteroids. Disease Markers, 2019, 2019, 1-7.	1.3	2
62	Efficacy and Safety of Honey Bee Venom (Apis mellifera) Dermal Injections to Treat Osteoarthritis Knee Pain and Physical Disability: A Randomized Controlled Trial. Journal of Alternative and Complementary Medicine, 2019, 25, 845-855.	2.1	17
63	Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer. Cancers, 2019, 11, 1548.	3.7	11
64	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
65	Prevalence and spectrum of MLH1, MSH2, and MSH6 pathogenic germline variants in Pakistani colorectal cancer patients. Hereditary Cancer in Clinical Practice, 2019, 17, 29.	1.5	9
66	Inherited variants in XRCC2 and the risk of breast cancer. Breast Cancer Research and Treatment, 2019, 178, 657-663.	2.5	13
67	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
68	A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia. Hematology, 2019, 24, 679-719.	1.5	18
69	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
70	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
71	The spectrum of mutations predisposing to familial breast cancer in Poland. International Journal of Cancer, 2019, 145, 3311-3320.	5.1	39
72	BARD1 is a Low/Moderate Breast Cancer Risk Gene: Evidence Based on an Association Study of the Central European p.Q564X Recurrent Mutation. Cancers, 2019, 11, 740.	3.7	25

#	Article	IF	Citations
73	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
74	Serum selenium level and cancer risk: a nested case-control study. Hereditary Cancer in Clinical Practice, 2019, 17, 33.	1.5	15
75	Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Research, 2019, 21, 144.	5.0	24
76	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
77	Iron levels, genes involved in iron metabolism and antioxidative processes and lung cancer incidence. PLoS ONE, 2019, 14, e0208610.	2.5	41
78	Plant SCPL acyltransferases: multiplicity of enzymes with various functions in secondary metabolism. Phytochemistry Reviews, 2019, 18, 303-316.	6.5	19
79	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
80	Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. Cancer Research, 2019, 79, 467-481.	0.9	22
81	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	1.9	81
82	A systematic literature review identifying associations between outcomes and quality of life (QoL) or healthcare resource utilization (HCRU) in schizophrenia. Journal of Medical Economics, 2019, 22, 403-413.	2.1	7
83	Inherited NBN Mutations and Prostate Cancer Risk and Survival. Cancer Research and Treatment, 2019, 51, 1180-1187.	3.0	21
84	The BRCA2 c.68-7TÂ>ÂA variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human Mutation, 2018, 39, 729-741.	2.5	19
85	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
86	A serine carboxypeptidase-like acyltransferase catalyzes synthesis of indole-3-acetic (IAA) ester conjugate in rice (Oryza sativa). Plant Physiology and Biochemistry, 2018, 125, 126-135.	5.8	18
87	Role of germline aberrations affecting CTNNA1, MAP3K6 and MYD88 in gastric cancer susceptibility. Journal of Medical Genetics, 2018, 55, 669-674.	3.2	37
88	Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland. Hereditary Cancer in Clinical Practice, 2018, 16, 6.	1.5	12
89	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	1.9	15
90	Cadmium effects on embryo growth of pea seeds during germination: Investigation of the mechanisms of interference of the heavy metal with protein mobilization-related factors. Journal of Plant Physiology, 2018, 226, 64-76.	3.5	21

#	Article	IF	Citations
91	Serum selenium levels predict survival after breast cancer. Breast Cancer Research and Treatment, 2018, 167, 591-598.	2.5	36
92	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078.	2.9	21
93	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	2.9	33
94	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
95	Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population. PLoS ONE, 2018, 13, e0201065.	2.5	30
96	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
97	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
98	Serum selenium levels and the risk of progression of laryngeal cancer. PLoS ONE, 2018, 13, e0184873.	2.5	25
99	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
100	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. European Journal of Human Genetics, 2017, 25, 432-438.	2.8	26
101	BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.9	75
102	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	7.4	1,898
103	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
104	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
105	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
106	Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. European Journal of Human Genetics, 2017, 25, 1246-1252.	2.8	34
107	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
108	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	6.3	242

#	Article	IF	Citations
109	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	1.9	45
110	Serum folate concentration and the incidence of lung cancer. PLoS ONE, 2017, 12, e0177441.	2.5	31
111	The 30 kb deletion in the APOBEC3 cluster decreases APOBEC3A and APOBEC3B expression and creates a transcriptionally active hybrid gene but does not associate with breast cancer in the European population. Oncotarget, 2017, 8, 76357-76374.	1.8	26
112	PHIP- a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 2017, 8, 102769-102782.	1.8	9
113	Conformational study of the 3,6-dihydro-2H-1,4-oxazin-2-one fragment in 8-tert-butyl-7-methoxy-8-methyl-9-oxa-6-azaspiro[4.5]decane-2,10-dione stereoisomers. Acta Crystallographica Section C, Structural Chemistry, 2017, 73, 556-562.	0.5	0
114	Usefulness of urinary kidney injury molecule-1 (KIM-1) in children with idiopathic nephrotic syndrome treated with cyclosporine A. Family Medicine and Primary Care Review, 2016, 2, 103-108.	0.2	0
115	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 2016, 7, 80140-80163.	1.8	31
116	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Medicine, 2016, 13, e1002105.	8.4	118
117	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
118	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	2.5	12
119	PARS PLANA VITRECTOMY IN ADVANCED CASES OF VON HIPPELâ€“LINDAU EYE DISEASE. Retina, 2016, 36, 325-334.	1.7	21
120	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	5.1	51
121	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Human Molecular Genetics, 2016, 25, 3600-3612.	2.9	17
122	Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?. International Journal of Cancer, 2016, 139, 601-606.	5.1	16
123	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
124	Patient survival and tumor characteristics associated with CHEK2:p.I157T â€“ findings from the Breast Cancer Association Consortium. Breast Cancer Research, 2016, 18, 98.	5.0	39
125	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
126	Cloning and biochemical characterization of indole-3-acetic acid-amino acid synthetase PsGH3 from pea. Plant Physiology and Biochemistry, 2016, 107, 9-20.	5.8	9

#	Article	IF	Citations
127	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	3.8	19
128	Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Research, 2016, 18, 22.	5.0	43
129	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	1.8	21
130	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88
131	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2016, 157, 319-327.	2.5	26
132	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	1.9	111
133	Abiotic stress and phytohormones affect enzymic activity of 1- O -(indole-3-acetyl)-Î²- d -glucose: myo -inositol indoleacetyl transferase from rice (Oryza sativa). Journal of Plant Physiology, 2016, 205, 93-96.	3.5	10
134	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	6.2	59
135	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 2016, 25, 3863-3876.	2.9	33
136	rs2735383, located at a microRNA binding site in the 3â€™UTR of NBS1, is not associated with breast cancer risk. Scientific Reports, 2016, 6, 36874.	3.3	2
137	A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome. Hereditary Cancer in Clinical Practice, 2016, 14, 14.	1.5	6
138	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	5.0	42
139	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
140	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
141	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Scientific Reports, 2016, 6, 32512.	3.3	19
142	Age- and Tumor Subtypeâ€“Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	1.6	152
143	BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population. Hereditary Cancer in Clinical Practice, 2016, 14, 3.	1.5	7
144	Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. Familial Cancer, 2016, 15, 289-296.	1.9	13

#	Article	IF	Citations
145	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility, 2016, 105, 781-785.	1.0	38
146	No evidence that protein truncating variants inBRIP1are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 2016, 53, 298-309.	3.2	94
147	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
148	The auxin conjugate indole-3-acetyl-aspartate affects responses to cadmium and salt stress in Pisum sativum L.. Journal of Plant Physiology, 2016, 191, 63-72.	3.5	54
149	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Human Genetics, 2016, 135, 137-154.	3.8	8
150	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	6.3	77
151	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	1.0	37
152	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
153	Abstract LB-196: A phase I open-label, fixed-sequence, two-period crossover study of the effect of multiple doses of Itraconazole on Palbociclib (PDâ€“0332991) pharmacokinetics in healthy volunteers. Cancer Research, 2016, 76, LB-196-LB-196.	0.9	2
154	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	2.5	26
155	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
156	Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer. Cancer Research and Treatment, 2016, 48, 1056-1064.	3.0	69
157	A molecular modelling explanation of the unexpected stereochemistry observed in the alkylation of oxazinone-derived glycine equivalents using 4-chloromethyl-1,3,2-dioxathiolane-2-oxide. Tetrahedron: Asymmetry, 2015, 26, 1408-1415.	1.8	2
158	Cyclic sulfates as useful tools in the asymmetric synthesis of 1-aminocyclopropane-1-carboxylic acid derivatives. Tetrahedron: Asymmetry, 2015, 26, 1261-1267.	1.8	7
159	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
160	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
161	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	5.0	26
162	Recurrent mutations of <scp>BRCA1</scp> and <scp>BRCA2</scp> in Poland: an update. Clinical Genetics, 2015, 87, 288-292.	2.0	35

#	Article	IF	Citations
163	Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair. Obstetrical and Gynecological Survey, 2015, 70, 758-762.	0.4	0
164	Review Selenium as aÂmarker of cancer risk and of selection for control examinations in surveillance. Wspolczesna Onkologia, 2015, 1A, 60-61.	1.4	4
165	Progress in the Search for New Dopamine Transporter Inhibitors. Current Medicinal Chemistry, 2015, 22, 3255-3277.	2.4	5
166	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
167	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
168	Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers. PLoS ONE, 2015, 10, e0130393.	2.5	22
169	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	6.3	428
170	Indole-3-acetic acid UDP-glucosyltransferase from immature seeds of pea is involved in modification of glycoproteins. Phytochemistry, 2015, 117, 25-33.	2.9	11
171	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	2.9	40
172	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	2.9	40
173	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76
174	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	2.8	14
175	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
176	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
177	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Research and Treatment, 2015, 150, 71-80.	2.5	103
178	Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 2015, 47, 888-897.	21.4	78
179	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
180	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	7.0	33

#	Article	IF	Citations
181	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	6.2	37
182	Germline RECQL mutations are associated with breast cancer susceptibility. Nature Genetics, 2015, 47, 643-646.	21.4	168
183	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	6.3	56
184	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
185	Cebranopadol: a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors. Expert Opinion on Investigational Drugs, 2015, 24, 837-844.	4.1	18
186	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
187	Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncology, The, 2015, 16, 638-644.	10.7	137
188	The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men. European Journal of Cancer Prevention, 2015, 24, 122-127.	1.3	5
189	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
190	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, 47, 1294-1303.	21.4	357
191	Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
192	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68
193	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	6.3	99
194	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. Journal of Clinical Oncology, 2015, 33, 2901-2907.	1.6	266
195	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	2.5	24
196	Asymmetric synthesis of all four stereoisomers of 1-amino-3-hydroxy-cyclopentane-1-carboxylic acid. Tetrahedron, 2015, 71, 686-693.	1.9	5
197	Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. Clinical Genetics, 2015, 88, 366-370.	2.0	34
198	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	2.9	38

#	Article	IF	Citations
199	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
200	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
201	CHAPTER 22. Selenium and Cancer. Food and Nutritional Components in Focus, 2015, , 377-390.	0.1	1
202	Abstract LB-159: Methylation of BRCA1 gene in blood is not inherited via maternal germ line and may predispose to triple-negative or medullary breast cancer. , 2015, , .		0
203	Possible association of the BRCA2 gene C5972T variant with gastric cancer: a study on Polish population. Polish Archives of Internal Medicine, 2015, 125, 39-45.	0.4	1
204	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	2.5	49
205	IAAâ€“amido synthetase activity and GH3 expression during development of pea seedlings. Acta Physiologiae Plantarum, 2014, 36, 3029-3037.	2.1	9
206	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	3.5	39
207	Long-term outcomes in idiopathic nephrotic syndrome: from childhood to adulthood. Clinical Nephrology, 2014, 81, 166-173.	0.7	50
208	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
209	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	2.9	53
210	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	5.0	97
211	Udp-Glycosyltransferases of Plant Hormones. Advances in Cell Biology, 2014, 4, 43-60.	1.5	40
212	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	5.0	57
213	The presence of prostate cancer at biopsy is predicted by a number of genetic variants. International Journal of Cancer, 2014, 134, 1139-1146.	5.1	6
214	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	2.9	32
215	Survival from breast cancer in patients with CHEK2 mutations. Breast Cancer Research and Treatment, 2014, 144, 397-403.	2.5	12
216	Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer. Breast Cancer Research and Treatment, 2014, 148, 615-622.	2.5	34

#	Article	IF	Citations
217	Consortium analysis of gene and geneâ€“folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	3.3	16
218	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. British Journal of Cancer, 2014, 110, 1088-1100.	6.4	21
219	Large deletion causing von Hippel-Lindau disease and hereditary breast cancer syndrome. Hereditary Cancer in Clinical Practice, 2014, 12, 16.	1.5	5
220	Zucapsaicin for the treatment of neuropathic pain. Expert Opinion on Investigational Drugs, 2014, 23, 1433-1440.	4.1	24
221	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105
222	Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. Breast Cancer Research and Treatment, 2014, 145, 553-562.	2.5	51
223	Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2014, 146, 421-427.	2.5	35
224	New investigational drugs for the treatment of neuropathic pain. Expert Opinion on Investigational Drugs, 2014, 23, 1093-1104.	4.1	37
225	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	2.9	12
226	The Effects of Dietary Cholesterol on Metabolism and Daily Torpor Patterns in Siberian Hamsters. Physiological and Biochemical Zoology, 2014, 87, 527-538.	1.5	5
227	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14
228	Pelvicalyceal system duplication with ectopic ureter â€“ diagnostic difficulties associated with the imaging procedure. Two cases report. Pediatria I Medycyna Rodzinna, 2014, 10, 315-321.	0.1	0
229	Can selenium levels act as a marker of colorectal cancer risk?. BMC Cancer, 2013, 13, 214.	2.6	33
230	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	21.4	326
231	The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. Prostate, 2013, 73, 542-548.	2.3	31
232	A common nonsense mutation of the BLM gene and prostate cancer risk and survival. Gene, 2013, 532, 173-176.	2.2	24
233	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	6.2	98
234	Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Journal of Clinical Oncology, 2013, 31, 3091-3099.	1.6	148

#	Article	IF	Citations
235	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
236	Clinical characteristics of breast cancer in patients with an NBS1 mutation. Breast Cancer Research and Treatment, 2013, 141, 471-476.	2.5	3
237	From Phenotype to Genotype: A New Twist on Identifying Genes Responsible for Inherited Hearing Loss. Human Mutation, 2013, 34, v-v.	2.5	2
238	Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?. Mutagenesis, 2013, 28, 625-629.	2.6	16
239	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	6.2	201
240	The risk of gastric cancer in carriers of CHEK2 mutations. Familial Cancer, 2013, 12, 473-478.	1.9	46
241	GH3 expression and IAA-amide synthetase activity in pea (Pisum sativum L.) seedlings are regulated by light, plant hormones and auxinic herbicides. Journal of Plant Physiology, 2013, 170, 361-368.	3.5	24
242	Genome-wide association studies identify four ER negativeâ€“specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	21.4	374
243	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
244	Application of NMR spectroscopy for assignment of the absolute configuration of 8â€tertâ€butylâ€2â€hydroxyâ€7â€methoxyâ€8â€methylâ€9â€oxaâ€6â€azaspiro[4.5]decâ€6â€enâ€10â€one. Chirality, 2013, 2	2.6	3
245	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. Breast Cancer Research and Treatment, 2013, 138, 273-279.	2.5	31
246	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	3.5	105
247	Are Two-Centimeter Breast Cancers Large or Small?. Current Oncology, 2013, 20, 205-211.	2.2	9
248	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
249	Genotyping by Induced FÃ¶rster Resonance Energy Transfer (iFRET) Mechanism and Simultaneous Mutation Scanning. Human Mutation, 2013, 34, n/a-n/a.	2.5	2
250	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
251	An inherited NBN mutation is associated with poor prognosis prostate cancer. British Journal of Cancer, 2013, 108, 461-468.	6.4	89
252	A personalised approach to prostate cancer screening based on genotyping of risk founder alleles. British Journal of Cancer, 2013, 108, 2601-2609.	6.4	16

#	Article	IF	Citations
253	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
254	A Low Selenium Level Is Associated with Lung and Laryngeal Cancers. PLoS ONE, 2013, 8, e59051.	2.5	46
255	The Synthesis of Enantiomers of 6-tert-Butyl-6-methylmorpholine-2,5- dione Using Wang Resin Supported Mukaiyama Reagent. Letters in Organic Chemistry, 2013, 10, 155-158.	0.5	1
256	Progress in the Glycine Equivalent Based α-Amino Acids Synthesis. Current Organic Synthesis, 2013, 10, 547-563.	1.3	12
257	Fungal urinary tract infection complicated by acute kidney injury in an infant with intestino-vesical fistula. Postepy Higieny I Medycyny Doswiadczalnej, 2013, 67, 719-721.	0.1	1
258	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	2.5	23
259	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	2.5	47
260	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 136, 295-302.	2.5	4
261	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	21.4	256
262	DNA and RNA analyses in detection of genetic predisposition to cancer. Hereditary Cancer in Clinical Practice, 2012, 10, 17.	1.5	6
263	11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 2012, 33, 1123-1132.	2.5	35
264	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	6.4	27
265	Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study. Cancer Causes and Control, 2012, 23, 1065-1074.	1.8	26
266	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	5.0	78
267	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	2.5	34
268	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	2.5	51
269	Synthesis of novel N-benzyl substituted piperidine amides of 1H-indole-5-carboxylic acid as potential inhibitors of cholinesterases. Acta Poloniae Pharmaceutica, 2012, 69, 449-55.	0.1	5
270	Selenium as marker for cancer risk and prevention. Polski Przeglad Chirurgiczny, 2012, 84, 470-5.	0.4	3

#	Article	IF	Citations
271	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptorâ€"Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	2.5	27
272	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	6.3	596
273	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	2.9	152
274	Smoking Related Cancers and Loci at Chromosomes 15q25, 5p15, 6p22.1 and 6p21.33 in the Polish Population. PLoS ONE, 2011, 6, e25057.	2.5	37
275	Association of MMP8 gene variation with an increased risk of malignant melanoma. Melanoma Research, 2011, 21, 464-468.	1.2	19
276	The CYP17A1 â^'34TÂ›ÂC polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2011, 126, 521-527.	2.5	3
277	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	3.8	18
278	Purification and Biochemical Characterization of Indole-3-acetyl-aspartic Acid Synthetase from Immature Seeds of Pea (Pisum sativum). Journal of Plant Growth Regulation, 2011, 30, 30-40.	5.1	8
279	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. International Journal of Cancer, 2011, 128, 2063-2074.	5.1	54
280	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	2.9	68
281	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038.	2.5	16
282	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Human Molecular Genetics, 2011, 20, 2263-2272.	2.9	22
283	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ€. Human Molecular Genetics, 2011, 20, 4693-4706.	2.9	71
284	Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer. Journal of Clinical Oncology, 2011, 29, 3747-3752.	1.6	207
285	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	7.0	47
286	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	6.3	40
287	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	5.6	91
288	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e20703.	2.5	21

#	Article	IF	Citations
289	The rs1447295 and DG8S737 markers on chromosome 8q24 and cancer risk in the Polish population. European Journal of Cancer Prevention, 2010, 19, 167-171.	1.3	13
290	BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Research and Treatment, 2010, 119, 201-211.	2.5	70
291	The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2010, 121, 639-649.	2.5	15
292	BRCA1 mutations and colorectal cancer in Poland. Familial Cancer, 2010, 9, 541-544.	1.9	33
293	CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland. Familial Cancer, 2010, 9, 605-608.	1.9	10
294	CHEK2 mutations and HNPCCâ€related colorectal cancer. International Journal of Cancer, 2010, 126, 3005-3009.	5.1	28
295	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	21.4	235
296	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	21.4	321
297	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	21.4	309
298	Exploring the Link between Germline and Somatic Genetic Alterations in Breast Carcinogenesis. PLoS ONE, 2010, 5, e14078.	2.5	33
299	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.9	169
300	Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology. Breast Cancer Research and Treatment, 2009, 114, 121-126.	2.5	13
301	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	21.4	276
302	Estrogen receptor status in CHEK2â€positive breast cancers: implications for chemoprevention. Clinical Genetics, 2009, 75, 72-78.	2.0	53
303	Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?. European Journal of Cancer, 2009, 45, 837-842.	2.8	34
304	Characterization of the c.190T>C missense mutation in BRCA1 codon 64 (Cys64Arg). International Journal of Oncology, 2009, 34, 1005-15.	3.3	7
305	A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. Breast Cancer Research and Treatment, 2008, 112, 367-368.	2.5	18
306	Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. Journal of Medical Genetics, 2008, 46, 132-135.	3.2	25

#	Article	IF	Citations
307	An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2008, 99, 974-977.	6.4	14
308	Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism. BMC Cancer, 2008, 8, 90.	2.6	5
309	Identification of enzyme activity that conjugates indole-3-acetic acid to aspartate in immature seeds of pea (Pisum sativum). Journal of Plant Physiology, 2008, 165, 564-569.	3.5	12
310	The VEGF_936_C>T 3â€²UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Letters, 2008, 262, 71-76.	7.2	46
311	Common variants of DNA repair genes and malignant melanoma. European Journal of Cancer, 2008, 44, 110-114.	2.8	36
312	Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis, 2008, 29, 762-765.	2.8	41
313	A Range of Cancers Is Associated with the rs6983267 Marker on Chromosome 8. Cancer Research, 2008, 68, 9982-9986.	0.9	111
314	BRCA1 mutations and prostate cancer in Poland. European Journal of Cancer Prevention, 2008, 17, 62-66.	1.3	33
315	Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland. European Journal of Cancer Prevention, 2008, 17, 389-391.	1.3	13
316	Integrin Â3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk. Journal of Medical Genetics, 2007, 44, 408-411.	3.2	11
317	AURKAF31I Polymorphism and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1416-1421.	2.5	30
318	The RAD51 135 G>C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA1 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 270-275.	2.5	59
319	Epistatic Relationship between the Cancer Susceptibility Genes CHEK2 and p27. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 572-576.	2.5	21
320	DNA Variation in MSR1, RNASEL and E-Cadherin Genes and Prostate Cancer in Poland. Urologia Internationalis, 2007, 79, 44-49.	1.3	20
321	RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	6.2	217
322	A deletion in CHEK2 of 5,395Âbp predisposes to breast cancer in Poland. Breast Cancer Research and Treatment, 2007, 102, 119-122.	2.5	102
323	CDKN2A-positive breast cancers in young women from Poland. Breast Cancer Research and Treatment, 2007, 103, 355-359.	2.5	22
324	The 3â€² untranslated region CÂ>ÂT polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation. Breast Cancer Research and Treatment, 2007, 104, 67-74.	2.5	15

#	Article	IF	Citations
325	Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Research and Treatment, 2007, 104, 299-308.	2.5	47
326	CYP1B1 and predisposition to breast cancer in Poland. Breast Cancer Research and Treatment, 2007, 106, 383-388.	2.5	18
327	BARD1 and breast cancer in Poland. Breast Cancer Research and Treatment, 2007, 107, 119-122.	2.5	26
328	Breast cancer susceptibility genes. Journal of B U on, 2007, 12 Suppl 1, S23-9.	0.4	5
329	A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. Journal of Medical Genetics, 2006, 43, 863-866.	3.2	103
330	Coverage of the Genetic Background of Breast Cancer in the Polish Population. Hereditary Cancer in Clinical Practice, 2006, 4, 25.	1.5	0
331	Low-risk Genes and Multi-organ Cancer Risk in the Polish Population. Hereditary Cancer in Clinical Practice, 2006, 4, 52.	1.5	1
332	CHEK2-Positive Breast Cancers in Young Polish Women. Clinical Cancer Research, 2006, 12, 4832-4835.	7.0	32
333	The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs. Hereditary Cancer in Clinical Practice, 2005, 3, 59.	1.5	26
334	Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study). Clinical Genetics, 2005, 69, 40-47.	2.0	34
335	Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization. International Journal of Cancer, 2005, 114, 230-236.	5.1	32
336	Breast cancer predisposing alleles in Poland. Breast Cancer Research and Treatment, 2005, 92, 19-24.	2.5	110
337	A specific enzyme hydrolyzing 6-O(4-O)-indole-3-ylacetyl-Î²-d-glucose in immature kernels of Zea mays. Journal of Plant Physiology, 2005, 162, 207-213.	3.5	30
338	German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. European Journal of Cancer, 2005, 41, 2896-2903.	2.8	39
339	The NOD2 3020insC Mutation and the Risk of Colorectal Cancer: Table 1. Cancer Research, 2004, 64, 1604-1606.	0.9	105
340	NBS1 Is a Prostate Cancer Susceptibility Gene. Cancer Research, 2004, 64, 1215-1219.	0.9	141
341	The auxin conjugate 1-O-indole-3-acetyl-Â-D-glucose is synthesized in immature legume seeds by IAGlc synthase and may be used for modification of some high molecular weight compounds. Journal of Experimental Botany, 2004, 55, 791-801.	4.8	29
342	A high proportion of founder BRCA1 mutations in Polish breast cancer families. International Journal of Cancer, 2004, 110, 683-686.	5.1	170

#	Article	IF	Citations
343	Breast Cancers with Ocular Metastases are Early Onset, Non-Familial and Non-BRCA1/BRCA2 Tumours. Hereditary Cancer in Clinical Practice, 2004, 2, 45.	1.5	0
344	Mutations in the von Hippel-Lindau Tumour Suppressor Gene in Central Nervous System Hemangioblastomas. Hereditary Cancer in Clinical Practice, 2004, 2, 93.	1.5	2
345	Germline 657del5 mutation in the NBS1 gene in breast cancer patients. International Journal of Cancer, 2003, 106, 379-381.	5.1	80
346	Hereditary ovarian cancer in Poland. International Journal of Cancer, 2003, 106, 942-945.	5.1	82
347	Bifunctional indole-3-acetyl transferase catalyses synthesis and hydrolysis of indole-3-acetyl-myo -inositol in immature endosperm of Zea mays. Physiologia Plantarum, 2003, 119, 165-174.	5.2	47
348	A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. European Journal of Human Genetics, 2003, 11, 955-958.	2.8	34
349	Germline 657del5 mutation in the NBS1 gene in patients with malignant melanoma of the skin. Melanoma Research, 2003, 13, 365-370.	1.2	30
350	Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 457-9.	2.5	18
351	BRCA2 gene mutations in families with aggregations of breast and stomach cancers. British Journal of Cancer, 2002, 87, 888-891.	6.4	75
352	Ovarian cancer of endometrioid type as part of the MSH6 gene mutation phenotype. Journal of Human Genetics, 2002, 47, 0529-0531.	2.3	12
353	1-Naphtalene acetic acid induces indole-3-ylacetylglucose synthase in Zea mays seedling tissue. Plant Growth Regulation, 2002, 38, 127-134.	3.4	15
354	Molecular basis of inherited predispositions for tumors.. Acta Biochimica Polonica, 2002, 49, 571-581.	0.5	3
355	Comparison of Alu-PCR, microsatellite instability, and immunohistochemical analyses in finding features characteristic for hereditary nonpolyposis colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2001, 127, 565-569.	2.5	8
356	Detection of mutations in theCOL4A5gene by SSCP in X-linked Alport syndrome. Human Mutation, 2001, 18, 141-148.	2.5	38
357	Detection of germline mutations in the BRCA1 gene by RNA-based sequencing. Human Mutation, 2001, 18, 149-156.	2.5	21
358	Novel RB1 gene constitutional mutations found in Polish patients with familial and/or bilateral retinoblastoma. Human Mutation, 2001, 18, 459-459.	2.5	19
359	Optimization of experimental conditions for RNA-based sequencing of MLH1 and MSH2 genes. Human Mutation, 2001, 17, 52-60.	2.5	19
360	Founder Mutations in the BRCA1 Gene in Polish Families with Breast-Ovarian Cancer. American Journal of Human Genetics, 2000, 66, 1963-1968.	6.2	222

#	Article	IF	Citations
361	Molecular Analyses in Diagnosis of High Genetic Predispositions to Malignancies.. Journal of Clinical Biochemistry and Nutrition, 2000, 28, 159-165.	1.4	0
362	Clinical Genetic Services for Familial Breast Cancer in Poland. Disease Markers, 1999, 15, 46-46.	1.3	1
363	Frequency and nature of germline Rb-1 gene mutations in a series of patients with sporadic unilateral retinoblastoma. European Journal of Cancer, 1999, 35, 1824-1827.	2.8	12
364	Age at diagnosis to discriminate those patients for whom constitutional DNA sequencing is appropriate in sporadic unilateral retinoblastoma. European Journal of Cancer, 1998, 34, 1919-1921.	2.8	17
365	Enzymatic Hydrolysis of 4-O and 6-O-Indol-3-Ylacetyl-Î²-D-Glucose in Plant Tissues. Journal of Plant Physiology, 1993, 142, 61-66.	3.5	30